Core Insights - DAFNA Capital Management sold 222,847 shares of Syndax Pharmaceuticals, valued at approximately $3.89 million, as reported in an SEC filing dated February 17, 2026 [1][2] - The value of Syndax's stake at the end of the fourth quarter decreased by $1.87 million due to share sales and price movements [2] Company Overview - Syndax Pharmaceuticals is a biotechnology company focused on developing novel cancer therapies, particularly for hematologic malignancies and immune-mediated conditions [5] - The company has a market capitalization of $2.1 billion and reported revenue of $172.4 million for the trailing twelve months (TTM) [4] - Syndax's net income for the TTM is reported at a loss of $285.4 million [4] Financial Performance - As of the latest report, Syndax shares are priced at $24.23, reflecting a 72% increase over the past year, significantly outperforming the S&P 500, which rose about 15% in the same period [7] - The fund's position in Syndax now represents 1.36% of its $430.52 million reportable assets, down from 1.90% in the previous quarter [7] Product Pipeline and Market Position - Syndax is advancing its pipeline with products like SNDX-5613 for acute myeloid leukemia and axatilimab for chronic graft versus host disease, alongside other therapies [8] - The company is transitioning from a clinical-stage to a commercial-stage biotech, generating real revenue and showing strong momentum from two commercial products [9] - This transition is significant but comes with increased operating costs and substantial ongoing losses [9] Strategic Insights - The recent share sale by DAFNA Capital Management indicates a disciplined approach to managing exposure within a biotech-heavy portfolio, especially after a significant stock price increase [6] - Syndax's ability to build a credible commercial base while advancing its pipeline positions it as a key innovator in the biopharmaceutical sector, though it may also lead to volatility as market expectations adjust [10]

Company Overview - Syndax Pharmaceuticals is a clinical-stage biotechnology company focused on developing novel cancer therapies, leveraging a targeted pipeline strategy for high-need oncology indications supported by strategic collaborations and licensing agreements [5][6] - As of the latest data, the company's stock price is $24.23, with a market capitalization of $2.1 billion and total revenue of $172.4 million over the trailing twelve months (TTM) [4][5] - The company reported a net income loss of $285.4 million (TTM), indicating ongoing cash burn due to high operating expenses related to research and development (R&D) and commercialization [4][9] Recent Transactions - Kynam Capital Management sold 469,041 shares of Syndax Pharmaceuticals, valued at approximately $8.18 million, during the fourth quarter of 2025, reducing its position to 10.81% of reportable 13F assets under management [2][5] - Following the sale, the value of Kynam's Syndax position increased by $38.07 million, reflecting both trading and share price movements [2] Performance Metrics - Syndax's stock has surged over 72% in the past year, significantly outperforming the S&P 500's approximate 15% gain during the same period [5] - The company generated about $172 million in total revenue last year, with approximately $124.8 million coming from its recently launched therapies, including Revuforj, and additional contributions from its Niktimvo collaboration [8] Investment Implications - The transaction by Kynam Capital Management suggests a strategic adjustment rather than a complete exit, as the remaining stake still represents a significant portion of their assets [10] - The ongoing tension between growth and profitability is evident, as the company continues to invest heavily in R&D while facing substantial net losses [9]

Group 1 - Brendan completed a Ph.D. at Stanford University in organic synthesis in 2009 [1] - He worked for Merck from 2009 to 2013 and has experience in biotech startups including Theravance and Aspira [1] - Brendan is a co-founder of 1200 Pharma, which spun out of Caltech and received significant investment in the eight figures [1] Group 2 - The author has a beneficial long position in the shares of SNDX and INCY [2] - The article expresses the author's own opinions and is not receiving compensation from any mentioned companies [2]

Company Overview - Syndax Pharmaceuticals is a commercial-stage organization focused on oncology, with two leading products targeting acute leukemia, specifically KMT2A and NPM1 acute leukemia, which together cover approximately 50% of the market for acute leukemia [3][4] Product Details - The company is a leader in the menin inhibitor class of drugs, being first to market and possessing a best-in-class profile [4] - The drug was launched in late 2024 and experienced significant sales growth throughout the last year, continuing into the current year [4]

Summary of Syndax Pharmaceuticals FY Conference Call Company Overview - **Company**: Syndax Pharmaceuticals (NasdaqGS:SNDX) - **Focus**: Oncology with two leading products targeting acute leukemia and chronic graft-versus-host disease (GVHD) [2][4] Key Products 1. **Revuforj**: - Targets KMT2A and NPM1 acute leukemia, covering approximately 50% of the acute leukemia market [2] - Launched in late 2024, with significant sales growth, achieving $152 million in sales in 2025 [3][4] - Expected to become the standard of care for NPM1 and relapsed refractory disease [6] - Anticipated average duration of therapy to increase from 4-6 months in 2025 to 6-12 months in 2026 due to maintenance therapy [10][11] 2. **Niktimvo**: - A CSF1R inhibitor for chronic GVHD, launched in early 2025 [3] - Achieved $152 million in sales within its first year [4] Market Position and Strategy - Syndax is positioned as a leader in the menin inhibitor class, with a broad label covering various indications [12] - The company emphasizes early treatment to improve patient outcomes, particularly in younger patients who can benefit from transplants [6][7] - Strong commercial and medical organization to support physician engagement and data dissemination [12][14] Financial Management - Operating expenses are maintained at $400 million for SG&A plus R&D, allowing for investment in both commercial and pipeline activities [19][20] - Successful product launches are contributing to gross margins that offset operational costs [20] Combination Therapy Insights - Revuforj is being used increasingly in combination therapies, with reported response rates of 70-80% compared to 50% for monotherapy [25] - The drug is well-tolerated in combination settings, with no significant incremental toxicity [26][27] - Physicians are encouraged to use Revuforj in combination due to its efficacy and safety profile [29] Clinical Trials and Future Directions - Ongoing studies focus on safety and efficacy in combination therapies, with endpoints including complete response rates and event-free survival [32][34] - The company is exploring the use of Revuforj in earlier treatment lines and in combination with other therapies [30][31] - Plans to announce clinical trial programs for myelofibrosis, leveraging promising preclinical data [40][41] Axatilimab Development - Axatilimab is showing promise in treating GVHD, with ongoing trials to assess its efficacy in combination with standard therapies [44][47] - The drug is expected to move into earlier lines of therapy based on positive data from ongoing studies [48][50] IPF Development - A phase 2 study (MAXRR) is underway, with plans for a phase 3 study contingent on favorable results [53][54] - The company is developing a subcutaneous formulation for potential use in phase 3 trials [54][55] Conclusion - Syndax Pharmaceuticals is strategically positioned in the oncology market with innovative therapies and a strong focus on combination treatments and early intervention strategies. The company is committed to maintaining operational efficiency while investing in future growth opportunities through clinical trials and product development.

Summary of Syndax Pharmaceuticals Conference Call Company Overview - **Company**: Syndax Pharmaceuticals (NasdaqGS:SNDX) - **Stage**: Commercial-stage company with two products in the market targeting acute leukemia and chronic graft-versus-host disease (GVHD) [5][6] Key Products 1. **Revuforj**: - Indications: KMT2A and NPM1 for acute leukemia - First-year sales: $125 million, with Q4 sales of $44.2 million, showing 38% growth from Q3 [8] - Expected to be a significant growth area as it becomes standard of care [11] 2. **Niktimvo**: - Indication: Chronic GVHD, launched in early 2025 - First-year sales (11 months): $152 million, with Q4 sales of $56 million, showing 22% growth from the prior quarter [9] Market Dynamics - **KMT2A**: High medical need, with a focus on early treatment to improve patient outcomes [11] - **NPM1**: Expected to contribute significantly to new patient additions, with a larger patient population compared to KMT2A [22] - **Relapse Refractory AML Market**: Approximately 6,000-6,500 patients, with frontline AML estimated at 20,000 patients, representing a potential market of $5-$7 billion [27][28] Growth Strategy - **2026 Outlook**: Continued penetration into KMT2A and NPM1 markets, with a focus on maintaining patients on therapy and increasing duration of treatment from 4-6 months to 6-12 months [14] - **Frontline Studies**: Two pivotal studies (REVEAL and EVOLVE-2) aimed at expanding into frontline treatment, with expectations for first readouts and approvals [31][33] Physician Education and Market Presence - Extensive education programs for healthcare professionals to optimize treatment approaches [18] - Strong presence at major medical congresses (ASH, ASCO, EHA) to disseminate data and educate on new treatment modalities [19][41] Long-term Opportunities - **Menin Inhibitors**: Potential expansion into myelofibrosis and idiopathic pulmonary fibrosis (IPF), with ongoing studies to explore these indications [36][49] - **Business Development**: Focus on in-licensing and developing additional oncology molecules, while maintaining a high bar for new opportunities [53] Financial Outlook - **Profitability Roadmap**: With nearly $400 million in cash and equivalents, the company is on track to profitability, supported by the successful launches of both products [61][62] - **Operating Expenses**: Commitment to keeping operating expenses flat while generating gross profit from product sales [61] Conclusion Syndax Pharmaceuticals is positioned for significant growth with its innovative therapies in acute leukemia and GVHD, backed by strong market dynamics, a clear growth strategy, and a focus on education and data dissemination within the medical community. The company is also exploring expansion into new therapeutic areas while maintaining a path to profitability.

Group 1: uniQure - uniQure upgraded to $35 by RBC and $60 by Wells Fargo, currently trading at $16.52, with a 53.33% increase over the past week [1] - The departure of Vinay Prasad from the FDA is viewed positively, with RBC assigning a 50% chance of drug approval for Huntington's disease [1] - Clinical data shows a 75% slowing in disease progression on cUHDRS and 60% on TFC, with a planned Type B meeting with the FDA in Q2 2026 [1] Group 2: Syndax - Syndax's price target raised to $45 from $33 by JPMorgan, currently trading at $23.23, with a consensus target of $38.09 [1] - The company is not currently receiving value for the Niktimvo IPF opportunity, with Phase 2 MAXPIRe data expected in Q4 2026 [1] - Q4 revenue for Revuforj was $44.20 million, up 38% sequentially, with management guiding toward profitability without additional capital raises [1] Group 3: Erasca - Erasca added to JPMorgan's "Positive Catalyst Watch list" ahead of the Phase 1 AURORAS-1 readout for ERAS-0015, expected in the first half of 2026 [1] - The firm sees potential share upside into the high-teens to high-$20s, with a year-end 2026 price target of $24 [1] - Erasca currently trades at $15.20, up 305.17% year-to-date, with a consensus target of $11.56 [1]

Summary of Syndax Pharmaceuticals FY Conference Call Company Overview - **Company**: Syndax Pharmaceuticals (NasdaqGS:SNDX) - **Industry**: Biotechnology, specifically focused on hematology and oncology - **Current Position**: The company has two commercial products in the hematology space, one for acute AML and the other for chronic GVHD, with three approvals in about a year [2][3] Core Points and Arguments Product Performance - **Revuforj**: - Generated $44 million in revenue in Q4 and $125 million for the full year, setting a record for first-year sales of an AML product [5] - KMT2A indication is the primary driver, with approximately 50% market penetration in its first year [5][6] - NPM1 indication has grown from 10% to over 30% of new patient starts following approval [7][8] - Total addressable market for both products combined is estimated to be upwards of $10 billion [3] Market Dynamics - **Patient Treatment**: - The company emphasizes the importance of treating patients earlier to improve outcomes and duration of therapy, which is expected to increase from 4-6 months in the first year to 6-12 months in the second year [11][12] - The total addressable market for KMT2A is about 2,000 patients, while for NPM1 it is approximately 4,500 patients, with pricing between $45,000-$50,000 per month [14][15] Growth Strategy - **Market Expansion**: - The company is evaluating regulatory options for European market entry and plans to conduct combination studies to position Revuforj in the first-line treatment setting [22][24] - The competitive landscape includes at least four other menin inhibitors, but Syndax believes it has the best profile and first-mover advantage [34] Financial Outlook - **Cash Position**: - Syndax ended the year with approximately $400 million in cash, with guidance to maintain flat operating expenses of $400 million for R&D and SG&A [49] Additional Important Information - **Niktimvo Performance**: - Revenue grew by 22% with 1,400 total prescriptions, and the drug is expected to penetrate earlier lines of treatment [37][39] - The market size for chronic GVHD is estimated at 6,500 patients in the refractory population and 15,000-17,000 in the front line, with potential revenue exceeding $5 billion [40][41] - **Research and Development**: - A phase 2 trial for idiopathic pulmonary fibrosis (IPF) is fully enrolled, with results expected in Q4 2026 [43][44] - The mechanism of action for the IPF trial involves targeting disease-causing macrophages, which have shown promise in previous studies [44][47] - **Investor Relations**: - Syndax is working to improve communication with analysts to ensure comprehensive consensus reporting on revenue expectations [10] This summary encapsulates the key points discussed during the conference call, highlighting the company's current status, product performance, market dynamics, growth strategies, and financial outlook.

Core Insights - Syndax Pharmaceuticals (NASDAQ:SNDX) is positioned as a strong investment opportunity in the cancer sector, with a solid start to 2026 driven by the performance of its key products [1][3] Group 1: Financial Performance - The company reported annual net sales of $125 million for Revuforj and $152 million for Niktimvo in the first 11 months, indicating quarter-over-quarter sales growth [3] - Revuforj's revenue growth is attributed to its increasing market penetration for KMT2A-rearranged acute myeloid leukemia [3] Group 2: Market Opportunities - Syndax is targeting a significant opportunity with Niktimvo in chronic graft-versus-host disease (cGVHD), with an initial patient target of 6,500 that could expand to approximately 17,000 [4] - The potential sales for Niktimvo in the third-line plus market could reach up to $1 billion [4] Group 3: Company Overview - Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company focused on developing innovative, first-in-class targeted therapies for cancer, particularly acute leukemia and cGVHD [5] - The company is known for its FDA-approved drugs Revuforj (revumenib) and Niktimvo (axatilimab-csfr) [5]

Financial Data and Key Metrics Changes - Total revenue for 2025 was $172.4 million, consisting of $124.8 million in Revuforj net revenue, $42.4 million of Niktimvo collaboration revenue, and $5.1 million in milestones and royalties [33] - Revuforj net revenue increased by 38% in the fourth quarter compared to the third quarter, driven by strong demand [33] - Niktimvo net revenue for 2025 reached $151.6 million, surpassing first-year launch benchmarks set by Rezurock [18][33] Business Line Data and Key Metrics Changes - Revuforj generated $125 million in net revenue in 2025, with a 38% growth in net revenue and a 35% growth in prescriptions quarter-over-quarter in Q4 [6][7] - Niktimvo saw a 22% increase in net revenue quarter-over-quarter in Q4, contributing $42 million in collaboration revenue to Syndax [8][9] Market Data and Key Metrics Changes - The KMT2A business showed continued growth as the number of patients on therapy post-transplant began to increase significantly [7] - The NPM1 market opportunity is estimated to triple the annual addressable patient population to 6,500 patients, with early data indicating strong uptake [13][15] Company Strategy and Development Direction - Syndax aims to expand its market share in menin inhibition, with Revuforj positioned as the leading menin inhibitor in both relapsed refractory and frontline settings [36] - The company is focused on advancing its pipeline, including pivotal trials for revumenib and axatilimab, to unlock significant market opportunities [22][28] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the continued success of Revuforj and Niktimvo, supported by strong customer relationships and clinical data [9][11] - The company is well-funded with $394 million in cash and equivalents, expecting to reach profitability without additional capital [35] Other Important Information - Syndax completed enrollment in the MAXPIRe trial for axatilimab in idiopathic pulmonary fibrosis, with top-line data expected in Q4 2026 [10][28] - The company anticipates stable expenses in 2026, guiding total R&D plus SG&A expenses to approximately $400 million [35] Q&A Session Summary Question: What factors are driving the increase in KMT2A maintenance therapy post-transplant? - Management noted that the growth in KMT2A has been significant, with a third of patients going to transplant and an increasing number returning for maintenance therapy, which is expected to continue growing [40][41] Question: What is the expected steady state for NPM1 patient starts? - Management indicated that they expect the percentage of NPM1 patient starts to grow significantly, potentially reaching a 50/50 split with KMT2A patients as awareness and access improve [43][45] Question: What are the criteria for determining the go-forward decision on the IPF indication? - Management highlighted the importance of statistical significance and clinical relevance against historical controls, with a focus on achieving a meaningful difference in forced vital capacity [47][49] Question: How quickly can a pivotal trial for IPF be initiated if the phase II trial reads out positively? - Management expressed intent to design and execute the next trial as quickly as possible, with plans for a phase III trial based on the positive results from the phase II study [52][53] Question: Are physicians comfortable with the dosing of Revuforj in maintenance therapy? - Management confirmed that physicians are becoming more comfortable with the dosing as maintenance use increases, supported by ongoing studies to optimize dosing [61][62] Question: What is the strategy for moving Revuforj into newly diagnosed fit KMT2A patients? - Management explained that they are pursuing innovative approaches, including trials with venetoclax, to potentially reduce morbidity while achieving similar outcomes to intensive chemotherapy [66][67]